Prosecutor Andrew Edis made the disclosure Thursday during Coulson's and Brooks' trial on phone hacking and other charges, the first major criminal case to go to court in the hacking saga that has shaken Britain's political, judicial and media elite.
Brooks, Coulson and six other people are now on trial, including Brooks' current husband Charles. All deny the various charges against them, which range from phone hacking to bribing officials for scoops to obstructing police investigations.
Edis said the relationship between Brooks and Coulson was relevant to the hacking case because it showed they trusted one another and shared intimate information.
10 Best Safest Stocks To Watch Right Now: Boston Therapeutics Inc (BTHE)
Boston Therapeutics, Inc. is a development-stage company. The Company�� business is the development, manufacture and commercialization of therapeutic drugs and dietary supplements with a focus on glyco-pathology, a specialized field involving understanding the importance of carbohydrates in biochemistry and progression of diseases. The Company is focusing on three products: IPOXYN, an injectable anti-hypoxia drug, which it is developing; PAZ320, which is a non-systemic, chewable drug candidate for reduction of blood glucose in diabetics in development and SUGARDOWN, a complex carbohydrate-based chewable dietary supplement, which it is marketing. The Company�� non-systemic compounds for prediabetes and diabetes, SUGARDOWN and PAZ320, belong to the class of carbohydrate-hydrolyzing enzyme inhibitors.
SUGARDOWN
The Company has developed SUGARDOWN, a non-systemic complex carbohydrate-based dietary supplement to moderate post-meal blood glucose using processes and technology. It has unrestricted access to both sufficient raw materials at commodity pricing and processing facilities to produce sufficient supply of SUGARDOWN to support product distribution across multiple sales channels as a dietary supplement. Its SUGARDOWN dietary supplement consists of a stabilized complex carbohydrate composition. The Company has completed development of SUGARDOWN as a dietary supplement. On January 24, 2012 the Company announced the clinical trial results in healthy volunteers performed at the University of Sydney on SUGARDOWN.
PAZ320
PAZ320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications. PAZ320 inhibits the enzymes, which release glucose from complex carbohydrate in foods during digestion, reducing the amount of available glucose absorbed through the intestine. PAZ320 is in development as a drug candidate. The Company�� non-systemic compounds for prediabetes and diabetes, SUGARDOWN and PAZ320, belong to the! class of carbohydrate-hydrolyzing enzyme inhibitors.
IPOXYN
The Company has developed a drug candidate product IPOXYN, a glyco-protein based therapeutic agent. Its IPOXYN anti-hypoxia drug consists of a stabilized glycoprotein composition containing oxygen-rechargeable iron, targeting both human and animal tissues and organ systems deprived of oxygen and in need of metabolic support. In addition to potential uses for human patients, it also focuses to file a registration for IPOXYN for veterinary applications under the name OXYFEX. The Company�� pharmaceutical agents are intended for intravenous administration into the circulatory system to target acute and late stage diseases.
Advisors' Opinion:- [By CRWE]
Today, BTHE remains (0.00%) +0.000 at $1.10 thus far (ref. google finance Delayed: 12:25PM EDT October 10, 2013).
Boston Therapeutics has previously closed the final tranche of approximately $1.8 million to bring total gross proceeds of approximately $5.3 million from the private placement of Common Stock and warrants to existing and new accredited investors (the “Offering”).
Proceeds of the offering will be used to fund additional clinical trials for PAZ320, a non-systemic chewable drug designed to reduce the elevation of postprandial glucose or post-meal blood sugar for treatment of patients with Type 2 diabetes, and for general corporate purposes. PAZ320 is the first compound in a new class of therapies for this disease.
Hot Gas Utility Stocks For 2014: First Trust Ise Global Engineering And Construction Index Fund (FLM)
First Trust ISE Global Engineering and Construction Index Fund (the Fund) seeks investment results that correspond generally to the price and yield of an equity index called the ISE Global Engineering and Construction Index (the Index). The Fund is a series of the First Trust Exchange-Traded Fund II, an investment company and an exchange-traded index fund. The Index is developed and owned by the International Securities Exchange, LLC (ISE or Index Provider), in consultation with Standard & Poor's, a Division of The McGraw-Hill Companies, Inc., which calculates and maintains the Index. The Index specifically targets companies that are engaged in civil and capital projects, such as infrastructure, utilities, transportation, telecommunications, commercial, residential and commerce facilities, and whose roles are within the engineering, designing, planning, consulting, project managing and/or constructing of these projects. First Trust Advisors L.P. is the investment adviser for the Fund. Advisors' Opinion:- [By John Udovich]
Small cap building materials stock NCI Building Systems Inc (NYSE: NCS) fell yesterday after announcing a share offering plus its investors have (so-far) missed out on any ��ecovery��in construction���meaning it might be time to take a closer look at the stock along with potential performance benchmarks like the PowerShares Dynamic Building & Construction ETF (NYSEARCA: PKB) and the First Trust ISE Global Engineering and Construction Index Fund ETF (NYSEARCA: FLM)���both of which have had decent returns in recent years.
- [By John Udovich]
Mid cap infrastructure construction stock Chicago Bridge & Iron Company N.V. (NYSE: CBI) fell 7.23% after being trashed in an article by an apparent�short seller posted on Seeking Alpha, meaning its worth taking a closer look at the stock along with the performance of potential benchmarks like Jacobs Engineering Group Inc (NYSE: JEC), KBR, Inc (NYSE: KBR) and First Trust ISE Global Engineering and Construction Index Fund ETF (NYSEARCA: FLM).
Hot Gas Utility Stocks For 2014: 1st Constitution Bancorp(NJ)
1st Constitution Bancorp operates as a bank holding company for 1st Constitution Bank that provides community banking services to corporations, individuals, partnerships, and other community organizations in the central and northeastern New Jersey area. It offers various deposit products, including noninterest bearing demand deposits, interest bearing demand deposits, savings deposits, and time deposits, as well as certificates of deposit, and money market and NOW accounts. The company also provides a range of loan products comprising commercial loans for working capital, business expansion, and the purchase of equipment and machinery; construction loans to real estate developers for the acquisition, development and construction of residential subdivisions; residential consumer loans; term loans; lines of credit; loans secured by equipment and receivables; second mortgage home improvement loans; home equity lines of credit; and non-residential consumer loans for automobile s, recreation vehicles, and boats, as well as secured and unsecured personal loans, and deposit account secured loans. It provides its services through a network of 14 branches. The company was founded in 1989 and is based in Cranbury, New Jersey.
Advisors' Opinion:- [By Mark Skousen]
And that brings me to Nidec (NJ). Based in Kyoto, Japan, Nidec manufactures small- to mid-size motors, fan motors, and pivot assemblies used in dozens of IT products, as well as home appliances, automobiles, office equipment, and industrial machinery.
- [By Monica Gerson]
Nidec (NYSE: NJ) shares climbed 2.75% to $20.17. The volume of Nidec shares traded was 506% higher than normal. Nidec's trailing-twelve-month revenue is $9.42 billion.
Hot Gas Utility Stocks For 2014: Sagent Pharmaceuticals Inc.(SGNT)
Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, sources, and markets pharmaceutical products, principally injectable-based generic equivalents to branded products in the United States. It offers a range of products across anti-infective, oncolytic, and critical care indications in various presentations, including single-and multi-dose vials, pre-filled ready-to-use syringes, and premix bags. The company?s anti-infective products include Levofloxacin, a fluoroquinolone antibacterial for the treatment of various infections caused by susceptible bacteria in adults of age 18 years or older; and Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structure, as well as moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients. Its oncology products comprise Gemcitabine, a nucleoside metabolic inhibitor used for the treatment of ovarian, breast, lung, and panc reatic cancers; and Topotecan, a topoisomerase inhibitor for small cell lung cancer sensitive disease. The company also offers critical care products consisting of Adenosine, an antiarrhythmic used for the treatment of cardiac rhythm disturbances; and Heparin, an anticoagulant used to prevent and treat blood clotting during and after surgery and dialysis. As of December 31, 2011, it marketed 33 generic injectable products; and had a new product pipeline that included 36 products represented by 63 Abbreviated New Drug Applications (ANDAs). The company sells its products to pharmaceutical wholesale companies, which then distribute the products to end-user hospitals, long-term care facilities, alternate care sites, and clinics. The company was formerly known as Sagent Holding Co. and changed its name to Sagent Pharmaceuticals, Inc. in April 2011. Sagent Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Schaumburg, Illinois.
Advisors' Opinion:- [By Roberto Pedone]
Sagent Pharmaceuticals (SGNT) is a pharmaceutical company engaged in developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. This stock closed up 1.1% at $23.58 in Thursday's trading session.
Thursday's Volume: 235,000
Three-Month Average Volume: 128,231
Volume % Change: 110%From a technical perspective, SGNT rose modestly higher here right above its 50-day moving average of $22.32 with above-average volume. This move pushed shares of SGNT into breakout territory, since the stock took out some near-term overhead resistance at $23.50. Shares of SGNT are now quickly moving within range of triggering another near-term breakout trade. That trade will hit if SGNT manages to clear its 52-week high at $24.27 with high volume.
Traders should now look for long-biased trades in SGNT as long as it's trending above its 50-day at $22.32 and then once it sustains a move or close above its 52-week high at $24.27 with volume that's near or above 128,231 shares. If that breakout hits soon, then SGNT will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are its next major overhead resistance levels at $26.74 to its all-time high at $29.23.
Hot Gas Utility Stocks For 2014: Aeropostale Inc (ARO)
Aeropostale, Inc., (Aeropostale), incorporated on September 1, 1995, is a mall-based, specialty retailer of casual apparel and accessories, principally targeting 14 to 17 year-old young women and men through its Aeropostale stores and 4 to 12 year-old kids through its P.S. from Aeropostale stores. P.S. from Aeropostale products can be purchased in P.S. from Aeropostale stores, in certain Aeropostale stores, and online at www.ps4u.com. As of January 28, 2012, it operated 986 Aeropostale stores, consisting of 918 stores in 50 states and Puerto Rico, 68 stores in Canada, as well as 71 P.S. from Aeropostale stores in 20 states. The Company designs, sources, markets and sells all of its own merchandise. In addition, pursuant to a licensing agreement, it operated 14 Aeropostale and P.S. from Aeropostale stores in Middle East and South East Asia. During March 2011, it announced that it had signed a second licensing agreement. The licensee to this agreement is focused to open approximately 30 stores in stores in Turkey over the next five years. In November 2012, the Company acquired online women's fashion footwear and apparel retailer GoJane.com (GoJane).
P.S. from Aeropostale offers casual clothing and accessories focusing on kids between the ages of 4 and 12. It�� P.S. from Aeropostale products are sold only at its stores and online through its e-commerce Websites, www.ps4u.com and www.aeropostale.com. The Company operates three street level stores in the New York City area. It also has a19,000 square foot Aeropostale store in the Times Square section of New York City. It offers both Aeropostale and P.S. from Aeropostale products in the Times Square store.
Advisors' Opinion:- [By Jayson Derrick]
Analysts at Jefferies maintained a Hold rating on Aeropostale (NYSE: ARO) with a price target lowered to $4 from a previous $5. Shares lost 9.97 percent, closing at $3.52.
- [By Hibah Yousuf]
Teen retailers can't catch a break: Any LFO summer girls still out there? Stores like Abercrombie & Fitch (ANF), American Eagle (AEO) and Aeropostale (ARO) will likely face another difficult quarter, as teens continue to abandon these once-hot retailers in favor of less expensive and fashion-forward outlets like Forever 21, H&M and Zara.
- [By Johanna Bennett]
After the closing bell, Walt Disney (DIS) rose 0.7% to $70.47 after announcing a 15% dividend hike. And teen retailer Aeropostale (ARO) fell 3.8% $9 after reporting fiscal third-quarter financial results.
- [By Will Ashworth]
Teen retail is having a brutal year. Revenues, profits and stock prices have all been hit hard. Abercrombie & Fitch (ANF), Aeropostale (ARO) and American Eagle Outfitters (AEO) have seen their stock prices drop by�25%, 30% and 19%, respectively, through Dec. 5.
Hot Gas Utility Stocks For 2014: Research in Motion Limited(RIMM)
Research In Motion Limited (RIM) designs, manufactures, and markets wireless solutions for the worldwide mobile communications market. The company, through the development of integrated hardware, software, and services, provides platforms and solutions for seamless access to time-sensitive information, including email, phone, short messaging service, and Internet and Intranet-based applications and browsing. Its products and services principally comprise the BlackBerry wireless platform, the RIM Wireless Handheld product line, software development tools, and other software and hardware. The company?s BlackBerry smartphones use wireless, push-based technology that delivers data to mobile users? business and consumer applications. Its BlackBerry smartphone portfolio includes BlackBerry Bold series, the BlackBerry Torch, BlackBerry Curve series, the BlackBerry Style, BlackBerry Storm series, the BlackBerry Tour, BlackBerry Pearl series, and the BlackBerry PlayBook tablet. T he company?s BlackBerry enterprise solutions comprise BlackBerry enterprise server, BlackBerry enterprise server express, BlackBerry mobile voice system, and hosted BlackBerry services. Its technology also enables third party developers and manufacturers to enhance their products and services through software development kits, wireless connectivity to data, and third-party support programs. In addition, the company offers BlackBerry technical support services, non-warranty repairs, and nonrecurring engineering services. Further, it provides BlackBerry App World that offers BlackBerry smartphone users an electronic catalogue that aids in the discovery and download/purchase of applications directly from their BlackBerry smartphone. The company markets and sells its BlackBerry wireless solutions primarily through global wireless communications carriers, and third party distribution channels. Research In Motion Limited was founded in 1984 and is headquartered in Waterloo, Canad a.
Advisors' Opinion:- [By Geoff Gannon] east loved of these is ��of course ��RIMM. Einhorn already has a paper loss in that stock. His average cost was $18.88 a share. Today�� price is $15.05. That�� a 20% loss. And Einhorn only started buying Research In Motion in the last three months of 2011.
But Research In Motion is a pretty small position ��0.81% of Einhorn�� total portfolio ��compared to one of his other new buys: Dell.
Einhorn already owns $255 million of Dell shares. He paid $15.36 a share. The stock is now at $18.08 a share. That�� an 18% gain. And Dell will mean a lot more to Einhorn�� performance than Research In Motion. Dell is a 3.9% position for Einhorn. That�� almost five times the size of his investment in Research In Motion. So ��for now at least ��Einhorn�� paper gain on Dell will more than make up for his paper loss on RIMM.
Finally, there�� Yahoo.
This is a quasi-new buy for Einhorn. He actually bought a 8.5 million shares of Yahoo in the first quarter of 2011 only to sell them for a 2% loss the next quarter. Einhorn was out of Yahoo completely for the third quarter of 2011. And now he�� back in with about 3 million shares bought in the fourth quarter of 2011. Einhorn�� average price is a wee bit lower this time. His original purchase price ��back in first quarter 2011 ��was $16.64 a share. He got his Yahoo shares about 6% cheaper this time around. Einhorn paid $15.66 a share for his 3 million shares of Yahoo. The stock is down a smidge from there. Around $15.25 a share.
There have been reports of a breakdown in Yahoo�� buyout talks. But that�� par for the course in a situation like this where a company is shopping itself around. There will be lots of people leaking stories for lots of different reasons. Don�� believe everything you read about Yahoo. And certainly don�� try to trade on everything you read about Yahoo.
Why is Einhorn buying Yahoo?
Probably on a sum of the parts basis. As everybod
- [By GuruFocus] rch-In-Motion is a high-profile case as renowned investor Prem Watsa bought into the company and sits on the company�� board. The stock was traded at above $140 in 2008. It has since lost more than 95%, traded at single digits and still sinking.
Again let�� take a look at its gross margin:
While BlackBerry was a must-have in the corporate world, the profit margin of Research-In-Motion has started to decline. This was well before Apple (AAPL) released its first iPhone. Again as pointed by Adib, value investors did not buy into RIMM while it was traded at $140 because the P/E ratio then was 45. Value investors bought into RIMM while it was traded at $30-40 because the P/E ratio was at 10. This was in 2009 and the decline in profit margin had been happening for three years.
Why You Should Avoid Margin Decliners?
The reason is simple. The company is losing its price power or it never had price power. Competition is eating into its market.
Will the profit margin of these companies ever recover sustainably? That is a ��oo-hard��question. We should avoid situations where we have to answer this question.
Will these companies ever become good investments? They may. But not until they become net-nets.
The Power of Margin Expansion
On the other hand, if a company can expand its profit margin, it has a competitive advantage. A good example here is Apple (AAPL), which is the king of all margin-expanding companies:
We all know what has happened to the stock of Apple.
What�� Next?
GuruFocus will release a feature called ��arning Signs��which will warn you about the problems a company may have, including margin declines.
In the meantime, our new ��ll-In-One Screener��allows you to screen for the companies that can expand profit margins or those with declining margins. Those with expanding profit margins (think Apple) at reasonable prices will mostly likely be rewarding. Those
- [By Holly LaFon]
In the fourth quarter, Yacktman�� biggest additions to his holdings were Research In Motion (RIMM) and Avon Products (AVP). He also surprised followers by venturing into financials, with new positions in Goldman Sachs (GS), Bank of America (BAC), State Street Corp. (STT) and Northern Trust Corp. (NTRS).
- [By Holly LaFon] epublic Corp, one of the 50 largest publicly held insurance organizations in the nation, engages primarily in commercial lines underwriting and has a client base of leading industrial and financial services companies.
Watsa has held Old Republic shares since prior to 2007. He has not added to his holding since the third quarter of 2008, and since then the stock rarely went higher than his first quarter 2008 purchase price of almost $14. The stock dropped to an average of $9 in the fourth quarter of 2011, and he bought 5,000 more shares, bringing his total holding to 35,000 shares.
For the full year 2011, Old Republic experienced a loss of $218.5 million, compared to $40.6 million in 2010, due to two factors. The company�� general and title insurance segments turned positive for the first time since 2007, which was offset by the record-high operating losses due to dramatically increased claim costs. All of its gain in net income for the final quarter of the year was from substantially increased investment gains.
Johnson & Johnson (JNJ)
Prem Watsa has had Johnson & Johnson (JNJ) in his portfolio since prior to 2007, and it is his largest holding. Most recently, he purchased 763,000 shares in the fourth quarter of 2011 at an average of $64 per share.
Johnson & Johnson was founded in 1886 and today is one of the most comprehensive health care businesses in the world. It also has several impressive achievements that qualifies it as one of the nation�� premier blue-chip stocks: 27 consecutive years of adjusted earnings increases, 49 consecutive years of dividend increases. Johnson & Johnson stock generated 4% total return for investors over the last 10 years, compared to 1.4% for the S&P 500.
Currently, Johnson & Johnson, in partnership with Pfizer (PFE), is working on Bapineuzumab, what it calls the drug industry�� ��est chance��to delay Alzheimer��. They plan to release results of the drug�� Phase III data in the se
Hot Gas Utility Stocks For 2014: John Hancock Premium Dividend Fund (PDT)
John Hancock Patriot Premium Dividend Fund II (the Fund) is a diversified closed-end management investment company. The Fund's investment objective is to provide high current income together with capital growth. The Fund invests in a diversified portfolio of dividend-paying preferred and common stocks. It invests at least 80% of its net assets in dividend-paying securities. The Fund will normally invest more than 65% of its total assets in securities of companies in the utilities industry. Preferred stocks and debt obligations in which the Fund invests are rated investment grade (at least BBB by Standard & Poor�� or Baa by Moody�� Investors Service) at the time of investment, or will be preferred stocks of issuers of investment-grade senior debt, or if not rated, will be of comparable quality as determined by the Fund�� investment advisor. The Fund will invest in common stocks of issuers, whose senior debt is rated investment grade, or in the case of issuers that have no rated senior debt outstanding, whose senior debt is considered by its advisor to be of comparable quality. Its portfolio includes common stocks, preferred securities and short-term investments.
In May 2007, the Fund completed the acquisition of John Hancock Patriot Preferred Dividend Fund. In June 2007, the Fund acquired Hancock John Patriot Global Dividend Fund and John Hancock Patriot Premium Div Fund I. On October 10, 2007, the Fund completed the acquisition of John Hancock Patriot Select Dividend Trust Fund.
The Fund invests in industries, such as multi-utilities, electric utilities, investment banking and brokerage, other diversified financial services, oil and gas exploration and production, gas utilities, consumer finance, life and health insurance, and integrated telecommunication services. John Hancock Patriot Premium Dividend Fund II�� investment advisor is John Hancock Advisers, LLC, a wholly owned subsidiary of John Hancock Financial Services, Inc., which is a subsidiary of Manulife Fina! ncial Corporation. The Fund�� sub-advisor is MFC Global Investment Management (U.S.), LLC.
Advisors' Opinion:- [By Ari Charney]
John Hancock Premium Dividend Fund (PDT) tends to allocate roughly 30% to 40% of the portfolio to equities and 60% to 70% to preferred stock, with the utilities and financial sectors as its main focus.
No comments:
Post a Comment